DEEP RESEARCH · JS Link (127120.KQ)

JS Link Deep Dive: From Genomics Company to "Non-China Rare-Earth Permanent Magnet" Strategic Materials Maker

Orbitech exits → Juseong CN Air takes over → Korea (Yesan) · Malaysia (Kuantan) · US (Georgia) tri-pole production — pairing Lynas feedstock with IRA tailwinds to reposition as a supply-chain security play

Date: 2025-12-27 · Personal research note · Source: Naver blog original

0. Bottom line first

Official fact: China controls >90% of rare-earth mining, refining, and magnet manufacturing. On 2025-01-07 Juseong CN Air acquired 3,192,341 shares (14.20%) of JS Link for ~KRW 23.94B (~KRW 7,498/share); a subsequent KRW 20B third-party private placement lifted stake to 24–26%. In July 2025, signed an MoU with Australia's Lynas for a 3,000-tonne/year magnet plant in Kuantan, Malaysia. In September 2025, announced an ~USD 223M (~KRW 300B) 3,000-tonne plant in Columbus, Georgia — ~520 jobs, target operation late 2027.

Interpretation: Seven straight years of operating losses + negative operating cash flow = the company cannot fund operations from earnings, let alone CAPEX — yet a ~KRW 590B market cap already prices in much of the magnet-business success. Macro tailwinds (China tightening + IRA + CRMA) are clearly favorable, but execution — Yesan yield ramp, Lynas definitive contract, US subsidies, OEM supply deals — is the litmus test.

1. Overview — a textbook "Strategic Pivot"

JS Link's recent moves go far beyond a rename or diversification. They are a strategic pivot that rewrites identity and viability. Founded in 2000 as a genomics / precision-medicine company, JS Link veered hard into NdFeB magnet manufacturing in 2025.

Two forces converge — (1) chronic losses and growth limits in the legacy biotech, and (2) a "de-China" rare-earth value chain opening up via US-China rivalry. NdFeB magnets are the "heart" of EV traction motors, wind turbines, defense, and UAM — demand is exploding — but supply is >90% Chinese. That fault line is JS Link's opportunity.

1.1 Milestone timeline

2. Governance overhaul — Juseong CN Air arrives, Orbitech exits

2.1 End of the Orbitech era — a financial exit

Orbitech (nuclear-plant inspection + aerospace precision parts) became DNA Link's largest shareholder via a third-party share issue in November 2023. The market hoped for precision-machining × biotech convergence, but practical integration was minimal. Orbitech expanded to 21.1% via CB purchases, then abruptly chose to exit in early 2025.

Official fact (estimate): Orbitech invested ~KRW 9B in DNA Link → recovered ~KRW 30B (control-premium share sale ~KRW 24B + CB gains). 3x+ return — a successful exit.

Interpretation: Rather than absorb the huge CAPEX risk of the magnet pivot, Orbitech harvested a near-PE-style return.

2.2 The new owner — Juseong CN Air

2.3 Acquisition logic — "logistics × resources" synergy

• Internalizing supply-chain logistics: Lynas → Korea/Malaysia processing → US export is a complex movement of materials. Juseong CN Air can capture this as a captive flow and grow its own revenue.
• North America network: Reduces the early-entry friction for the Columbus, Georgia plant.
• Government affairs & lobbying: The Baker & Hostetler engagement is a foothold for securing IRA tax credits and DoD grants — a speed only possible with a globally savvy parent.

3. Why pivot — genomics to permanent magnets

3.1 Structural limits of the legacy biotech

For 20+ years JS Link ran disease-prediction and diagnostic services on genomics. But the small Korean market, fierce competition, and high R&D burden produced seven consecutive years of operating losses. The 3Q 2025 report still shows operating losses + continuing negative operating cash flow. Management concluded that biotech alone cannot lift corporate value — or even ensure survival.

3.2 The rare-earth magnet "super-cycle"

• Demand explosion: EV traction motors, offshore wind turbines, robotics, UAM — permanent magnets are no longer "industry vitamins" but the "industry heart".
• Supply crisis: China holds >90% of mining + refining + magnet manufacturing and uses it as a resource-weapon lever.
• De-China opportunity: US IRA and EU CRMA introduce massive subsidies and rules to reduce China dependence — opening a wide door for non-China players.

4. Operations strategy — a tri-pole global production system

4.1 Yesan (Chungnam) — domestic tech hub

• Location/scale: Ochuri, Godeok-myeon, Yesan-gun; 10,208 m². Broke ground March 2025, occupancy approval November 2025.
• Capacity: 1,000 tonnes/year — enough for ~500k EV traction motors.
• Status: Major equipment (large smelting furnaces for alloy flake precursor) installed by Sep 2025; pilot production underway. Samples will be supplied to Hyundai Motor, Kia, and other domestic / overseas customers for qualification.
• Tech: Recruited Japanese magnet expert Kenji Konishi (and others) to acquire sintering and grain-boundary diffusion know-how.

4.2 Kuantan, Malaysia — feedstock proximity (Lynas JV)

• July 2025 MoU with Australia's Lynas for a 3,000-tonne/year magnet plant in Kuantan.
• Adjacent to Lynas's LAMP refining facility → immediate oxide supply, lower logistics cost, total feedstock stability.
• Malaysian PM Anwar Ibrahim noted JS Link has completed site purchase and finalized investment — the project has moved past MoU into execution.

4.3 Columbus, Georgia (USA) — market beachhead

• ~USD 223M (~KRW 300B) investment, 3,000 tonnes/year, ~520 jobs, target operation late 2027.
• Heart of the US "Battery Belt" — Hyundai HMGMA + SK On and other battery cell makers cluster nearby.
• US production satisfies IRA critical-mineral / component rules — DoD / DOE grants are expected, with federal-government talks underway.

5. Financials — the bright and dark sides of mega-investment

5.1 Cash flow and profitability

The 3Q 2025 report still shows operating losses. Biotech weakness continues, while magnet-business hiring, R&D, and CAPEX prepayments inflate SG&A and CAPEX. Operating cash flow remains negative — the company can't cover operations from earnings, let alone investment. External funding is a survival condition.

5.2 Aggressive financing — CB + private placements

• Convertible bonds: Multiple issuances from 2H 2024 through 2025. The 15th-series CB and others raised ~KRW 37.1B. Interest cost is low but conversion creates dilution overhang; refixing clauses also add downside-conversion risk.
• Private placement: Third-party allotment to Juseong CN Air for KRW 20B — improved capital structure and entrenched control, but minority dilution.

5.3 Market view and risks

Market cap ~KRW 590B — rich for a loss-maker; magnet-business success is largely priced in. Risks to monitor:

• Neodymium price volatility: Off 2022 peaks, recently bouncing — sharp spikes raise working-capital pressure.
• Execution capability: Can a former biotech ramp the precision-controlled sintering process to stable yields fast enough? The "Valley of Death" between pilot and mass production is the binary question.
• Geopolitics: Tightening Chinese controls boost JS Link's value, but a US-China thaw or Chinese dumping would erode price competitiveness.

6. Conclusion & outlook

JS Link is making the most dangerous yet most compelling bet in its corporate history. Shedding the biotech shell and diving into the front line of the global supply-chain war is timely. The Orbitech exit and the Juseong CN Air arrival are not a routine ownership swap — they mark JS Link's evolution from an "investment vehicle" into a "real manufacturing + logistics platform".

Juseong CN Air's logistics + Lynas's feedstock + the Yesan-Kuantan-Columbus triangle — on paper a perfect "Non-China supply chain" puzzle. But the only thing that turns theory into reality is execution:

• Yesan yield stabilization
• Definitive Lynas contract
• Securing US government subsidies
• Supply contracts with global OEMs

Investors should track financial health (need for further funding) and watch quarterly disclosures for the timing of first magnet-business revenue and order wins. JS Link is no longer a biotech theme — it now stands before the market as a "supply-chain security" stock leveraging geopolitical risk into opportunity.